Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Date:

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Temu vende copias de marcas noruegas: – No tienen derecho

NRK No tienen derecho a hacer esto. Es un claro...

Protests live updates: Multiple arrests in NYC as LA enters 6th night of protests

ABC ByJack Moore, Riley Hoffman, Kevin Shalvey, Leah Sarnoff, and...

La administración Trump elimina la sección «Seguridad» del Instituto de Seguridad de IA

NBC Por Bruna Horvath La administración Trump dice que está reformando un...